Dr Richard Nicholas

Publications


Journals

  • Parsons N; Friede T; Todd S; Marquez EV; Chataway J; Nicholas R; Stallard N. (1 May 2012). An R package for implementing simulations for seamless phase II/III clinical trials using early outcomes for treatment selection. COMPUTATIONAL STATISTICS & DATA ANALYSIS. 56:1150-1160. Author weblink DOI.
  • Nicholas R; Rashid W. (2012). Multiple sclerosis. Clin Evid (Online). 2012.
  • Durrenberger PF; Ettorre A; Kamel F; Webb LV; Sim M; Nicholas RS; Malik O; Reynolds R; et alBoyton RJ; Altmann DM. (2012). Innate immunity in multiple sclerosis white matter lesions: expression of natural cytotoxicity triggering receptor 1 (NCR1). J Neuroinflammation. 9:1. DOI.
  • Thapar A; Lane T; Nicholas R; Friede T; Ellis M; Assenheim J; Franklin IJ; Davies AH. (Dec 2011). Systematic review of sonographic chronic cerebrospinal venous insufficiency findings in multiple sclerosis. Phlebology. 26:319-325. DOI.
  • Chataway J; Awad M; Meadmore K; Alsanousi A; Frost C; Chandler K; Merrick K; Wilkie D; et alNicholas R; Chan D. (1 Sep 2011). COGNITIVE AND NEUROPSYCHIATRIC STATUS IN A LARGE COHORT OF PATIENTS WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 82. DOI.
  • Howell OW; Reeves CA; Nicholas R; Carassiti D; Radotra B; Gentleman SM; Serafini B; Aloisi F; et alRoncaroli F; Magliozzi R; Reynolds R. (Sep 2011). Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain. 134:2755-2771. DOI.
  • Imperial College CCSVI Investigation Group; Thapar A; Lane TR; Pandey V; Shalhoub J; Malik O; Ellis M; Franklin IJ; et alNicholas R; Davies AH. (Sep 2011). Internal jugular thrombosis post venoplasty for chronic cerebrospinal venous insufficiency. Phlebology. 26:254-256. DOI.
  • Nicholas R; Chataway J. (2009). Multiple sclerosis. Clin Evid (Online). 2009.
  • Reynolds R; Roncaroli F; Nicholas R; Radotra B; Gveric D; Howell O. (Aug 2011). The neuropathological basis of clinical progression in multiple sclerosis. Acta Neuropathol. 122:155-170. DOI.
  • Nicholas R; Giannetti P; Alsanousi A; Friede T; Muraro PA. (2011). Development of oral immunomodulatory agents in the management of multiple sclerosis. Drug Des Devel Ther. 5:255-274. DOI.
  • Nicholas R; Straube S; Schmidli H; Schneider S; Friede T. (Oct 2011). Trends in annualized relapse rates in relapsing-remitting multiple sclerosis and consequences for clinical trial design. Mult Scler. 17:1211-1217. DOI.
  • Bentley P; Wang T; Malik O; Nicholas R; Ban M; Sawcer S; Sharma P. (Aug 2011). CADASIL with cord involvement associated with a novel and atypical NOTCH3 mutation. J Neurol Neurosurg Psychiatry. 82:855-860. DOI.
  • Friede T; Nicholas R; Stallard N; Todd S; Parsons N; Valdes-Marquez E; Chataway J. (1 Nov 2010). Refinement of the Clinical Scenario Evaluation Framework for Assessment of Competing Development Strategies With an Application to Multiple Sclerosis. DRUG INFORMATION JOURNAL. 44:713-718.
  • Magliozzi R; Howell OW; Reeves C; Roncaroli F; Nicholas R; Serafini B; Aloisi F; Reynolds R. (Oct 2010). A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol. 68:477-493. DOI.
  • Chataway J; Nicholas R; Todd S; Miller DH; Parsons N; Valdés-Márquez E; Stallard N; Friede T. (Jan 2011). A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis. Mult Scler. 17:81-88. DOI.
  • Nicholas R; Young C; Friede T. (Nov 2010). Bladder symptoms in multiple sclerosis: a review of pathophysiology and management. Expert Opin Drug Saf. 9:905-915. DOI.
  • Anderson JM; Patani R; Reynolds R; Nicholas R; Compston A; Spillantini MG; Chandran S. (May 2010). Abnormal tau phosphorylation in primary progressive multiple sclerosis. Acta Neuropathol. 119:591-600. DOI.
  • Marini-Bettolo C; Lane R; Charles P; Naresh K; Nicholas R; Singh P; Cohen A; Mackie P; et alRoncaroli F. (1 Dec 2009). Myopathy secondary to intravascular large B-cell lymphoma. NEUROMUSCULAR DISORDERS. 19:856-859. Author weblink DOI.
  • Nicholas R; Chataway J. (2007). Multiple sclerosis. Clin Evid (Online). 2007.
  • Anderson JM; Patani R; Reynolds R; Nicholas R; Compston A; Spillantini MG; Chandran S. (May 2009). Evidence for abnormal tau phosphorylation in early aggressive multiple sclerosis. Acta Neuropathol. 117:583-589. DOI.
  • Nicholas RS; Friede T; Hollis S; Young CA. (1 Jan 2009). Anticholinergics for urinary symptoms in multiple sclerosis. COCHRANE DATABASE OF SYSTEMATIC REVIEWS. . DOI.
  • Mills RJ; Young CA; Nicholas RS; Pallant JF; Tennant A. (1 Jan 2009). Rasch analysis of the Fatigue Severity Scale in multiple sclerosis. MULTIPLE SCLEROSIS. 15:81-87. Author weblink DOI.
  • Papadopoulos D; Dukes S; Patel R; Nicholas R; Vora A; Reynolds R. (Apr 2009). Substantial archaeocortical atrophy and neuronal loss in multiple sclerosis. Brain Pathol. 19:238-253. DOI.
  • Mills RJ; Nicholas RS; Malik O; Young CA. (1 Aug 2007). Rasch analysis of the fatigue severity scale in multiple sclerosis. EUROPEAN JOURNAL OF NEUROLOGY. 14:285-285. Author weblink.
  • Magliozzi R; Howell O; Vora A; Serafini B; Nicholas R; Puopolo M; Reynolds R; Aloisi F. (1 Apr 2007). Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. BRAIN. 130:1089-1104. Author weblink DOI.
  • Nicholas RS; Winter J; Wren P; Bergmann R; Woolf CJ. (1999). Peripheral inflammation increases the capsaicin sensitivity of dorsal root ganglion neurons in a nerve growth factor-dependent manner. Neuroscience. 91:1425-1433.
  • Wing MG; Seilly DJ; Nicholas RS; Rahman S; Zajicek J; Lachmann PJ; Compston DA. (1 Feb 1999). Comparison of C1q-receptors on rat microglia and peritoneal macrophages. J Neuroimmunol. 94:74-81.
  • Freeman JA; Playford ED; Nicholas RS; Thompson AJ. (Jan 1996). A neurological rehabilitation unit: audit of activity and outcome. J R Coll Physicians Lond. 30:21-26.
  • Ford H; Nicholas R. (Dec 2005). Multiple sclerosis. Clin Evid. 1637-1651.
  • Jenkinson MD; Simpson C; Nicholas RS; Miles J; Findlay GF; Pigott TJ. (Feb 2006). Outcome predictors and complications in the management of intradural spinal tumours. Eur Spine J. 15:203-210. DOI.
  • Vora AJ; Nicholas RS; Malik O; Graeber M; Roncaroli F; Gentleman S; Reynolds R. (1 Jun 2006). The UK Multiple Sclerosis Tissue Bank - a resource for research. JOURNAL OF NEURAL TRANSMISSION. 113:XIV-XIV. Author weblink.
  • Nicholas RS; Compston A; Brown DR. (Mar 2001). Inhibition of tumour necrosis factor-alpha (TNFalpha)-induced NF-kappaB p52 converts the metabolic effects of microglial-derived TNFalpha on mouse cerebellar neurones to neurotoxicity. J Neurochem. 76:1431-1438.
  • Nicholas RS; Wing MG; Compston A. (Mar 2001). Nonactivated microglia promote oligodendrocyte precursor survival and maturation through the transcription factor NF-kappa B. Eur J Neurosci. 13:959-967.
  • Nicholas RS; Stevens S; Wing MG; Compston DA. (Mar 2002). Microglia-derived IGF-2 prevents TNFalpha induced death of mature oligodendrocytes in vitro. J Neuroimmunol. 124:36-44.
  • Nicholas R; Stevens S; Wing M; Compston A. (23 May 2003). Oligodendroglial-derived stress signals recruit microglia in vitro. Neuroreport. 14:1001-1005. DOI.
  • Nicholas RS; Partridge J; Donn RP; Hawkins C; Boggild MD. (Jul 2003). The role of the PTPRC (CD45) mutation in the development of multiple sclerosis in the North West region of the United Kingdom. J Neurol Neurosurg Psychiatry. 74:944-945.
  • Majed HH; Chandran S; Niclou SP; Nicholas RS; Wilkins A; Wing MG; Rhodes KE; Spillantini MG; et alCompston A. (8 Feb 2006). A novel role for Sema3A in neuroprotection from injury mediated by activated microglia. J Neurosci. 26:1730-1738. DOI.

Conferences

  • Ettorre A; Kamel FO; Durrenberger PF; Traherne J; Giannetti P; Malik O; Nicholas R; Trowsdale J; et alBoyton RJ; Altmann DM. KIR expression as a biomarker of multiple sclerosis disease type. Annual Congress of the British-Society-for-Immunology, 5 Dec 2011 - 8 Dec 2011. 135:172-172. WILEY-BLACKWELL (1 Dec 2011).
  • Kamel F; Ettorre A; Durrenberger PF; Malik O; Nicholas R; Boyton R; Altmann D. Altered invariant natural killer T cells in multiple sclerosis. Annual Congress of the British-Society-for-Immunology, 5 Dec 2011 - 8 Dec 2011. 135:41-41. WILEY-BLACKWELL (1 Dec 2011).
  • Friede T; Parsons N; Stallard N; Todd S; Marquez EV; Chataway J; Nicholas R. Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: An application in multiple sclerosis. 6th International Meeting on Statistical Methods in Biopharmacy, Sep 2009. 30:1528-1540. WILEY-BLACKWELL (15 Jun 2011). DOI.
  • Giannetti P; Politis M; Su P; Turkheimer F; Wu K; Reynolds R; Nicholas R; Piccini P. Two different roles for microglia in vivo in T1 black holes in relapsing and progressive multiple sclerosis?. 21st Meeting of the European-Neurological-Society, 28 May 2011 - 31 May 2011. 258:221-221. SPRINGER HEIDELBERG (1 May 2011). Author weblink.
  • Howell OW; Reeves C; Carassiti D; Nicholas R; Radotra B; Gentleman S; Roncaroli F; Aloisi F; et alMagliozzi R; Reynolds R. The distribution of B-cell follicle-like structures in the cerebral meninges and their association with extensive inflammation and demyelination in multiple sclerosis. 112th Meeting of the British-Neuropathological-Society, 5 Jan 2011 - 7 Jan 2011. 37:27-27. WILEY-BLACKWELL PUBLISHING, INC (1 Jan 2011). Author weblink.
  • Harris AJ; Durrenberger P; Kamel F; Ettorre A; Nicholas R; Malik O; Altmann DM. Investigating the role of natural killer cell subsets in multiple sclerosis. Annual Congress of the British-Society-for-Immunology, 6 Dec 2010 - 10 Dec 2010. 131:125-125. WILEY-BLACKWELL PUBLISHING, INC (1 Dec 2010). Author weblink.
  • Nicholas R; D'Arcy C; Muraro P; McGuigan C; Malik O; Giannetti P; O'Driscoll S. USING NATALIZUMAB IN HIGHLY ACTIVE RELAPSING REMITTING MULTIPLE SCLEROSIS IN THE UK. Annual Meeting of the Association-of-British-Neurologists, 11 May 2010 - 14 May 2010. 81:E53-E53. B M J PUBLISHING GROUP (1 Nov 2010). Author weblink DOI.
  • Mattoscio M; Nicholas R; Malik O; Mc Guigan C; Dazzi F; Muraro PA. Functional relevance of haematopoietic stem cell mobilization following therapeutic alpha 4-integrin blockade in multiple sclerosis: preliminary data. 20th Meeting of the European-Neurological-Society, 19 Jun 2010 - 23 Jun 2010. 257:S221-S221. SPRINGER HEIDELBERG (1 Jun 2010).
  • Chataway J; Nicholas R; Todd S; Stallard N; Valdes-Marquez E; Parsons N; Friede T. Adaptive seamless trial designs in neurology: a case study in secondary progressive multiple sclerosis. 19th World Congress of Neurology, 24 Oct 2009 - 30 Oct 2009. 285:S113-S114. ELSEVIER SCIENCE BV (1 Oct 2009).
  • Chataway J; Nicholas R; Stallard N; Todd S; Parsons N; Valdes-Marquez E; Friede T. DEVELOPING A NEW TRIAL DESIGN IN SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS: A SEAMLESS ADAPTIVE APPROACH. ABN Joint Annual Meeting/Spanish-Society-of-Neurology, 22 Jun 2009 - 26 Jun 2009. 80. B M J PUBLISHING GROUP (1 Nov 2009). Author weblink DOI.
  • Wakerley BR; Hanspall M; Malik O; Nicholas R; McGuigan C. REASSESSING THE USE OF MITOXANTRONE IN MULTIPLE SCLEROSIS. ABN Joint Annual Meeting/Spanish-Society-of-Neurology, 22 Jun 2009 - 26 Jun 2009. 80. B M J PUBLISHING GROUP (1 Nov 2009). Author weblink DOI.
  • Magliozzi R; Howell OW; Durrenberger PF; Nicholas R; Roncaroli F; Aloisi F; Reynolds R. Cell and molecular changes in the grey matter of secondary progressive multiple sclerosis cases in response to meningeal inflammation. 25th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, 9 Sep 2009 - 12 Sep 2009. 15:S174-S174. SAGE PUBLICATIONS LTD (1 Sep 2009).
  • Nicholas R; Chataway J; Todd S; Stallard N; Valdes-Marquez E; Parsons N; Friede T. Adaptive clinical trials incorporating treatment selection and evaluation: methodology and application in progressive multiple sclerosis. 25th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, 9 Sep 2009 - 12 Sep 2009. 15:S142-S143. SAGE PUBLICATIONS LTD (1 Sep 2009). Author weblink.
  • Howell OW; Reeves C; Magliozzi R; Carassiti D; Nicholas R; Radotra B; Gentlemen S; Roncaroli F; et alAloisi F; Reynolds R. The incidence of meningeal B-cell follicles in secondary progressive multiple sclerosis: a neuropathological study of 96 cases. 25th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, 9 Sep 2009 - 12 Sep 2009. 15:S5-S5. SAGE PUBLICATIONS LTD (1 Sep 2009). Author weblink.
  • Nicholas R; Magliozzi R; Mahad D; Polito A; Roncaroli F; Reynolds R. Diffuse mitochondrial and neuronal damage ill the temporal cortex of multiple sclerosis patients is associated with increased occurrence of seizures. 13th Annual Meeting of the Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/24th Congress of the European-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/5th Congress of the Latin-Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis, 17 Sep 2008 - 20 Sep 2008. 14:S275-S275. SAGE PUBLICATIONS LTD (1 Sep 2008). Author weblink.
  • Howell OW; Magliozzi R; Nicholas R; Roncaroli F; Aloisi F; Reynolds R. Substantial pyramidal cell loss in the motor cortex of secondary progressive multiple sclerosis cases with meningeal B-cell follicles. 13th Annual Meeting of the Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/24th Congress of the European-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/5th Congress of the Latin-Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis, 17 Sep 2008 - 20 Sep 2008. 14:S272-S273. SAGE PUBLICATIONS LTD (1 Sep 2008).
  • Gveric D; Nicholas R; Roncaroli F; Gentleman S; Reynolds R. The UK Multiple Sclerosis Tissue Bank: resource for research. 13th Annual Meeting of the Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/24th Congress of the European-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/5th Congress of the Latin-Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis, 17 Sep 2008 - 20 Sep 2008. 14:S272-S272. SAGE PUBLICATIONS LTD (1 Sep 2008). Author weblink.
  • Scalfari A; Degenhardt A; Neuhaus A; Harner N; Seemueller S; Nicholas R; Mularo PA; Daumer M; et alEbers G. The role of relapses affecting the long-term disability outcome in multiple sclerosis in the London Ontario database. 13th Annual Meeting of the Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/24th Congress of the European-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/5th Congress of the Latin-Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis, 17 Sep 2008 - 20 Sep 2008. 14:S198-S198. SAGE PUBLICATIONS LTD (1 Sep 2008). Author weblink.
  • Chataway J; Chan D; Anderson V; Polito B; Kallis C; Frost C; Calder V; Greenwood J; et alNicholas R. The MS-STAT trial: a Phase II trial of high dose simvastatin in secondary progressive multiple sclerosis. 13th Annual Meeting of the Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/24th Congress of the European-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/5th Congress of the Latin-Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis, 17 Sep 2008 - 20 Sep 2008. 14:S36-S37. SAGE PUBLICATIONS LTD (1 Sep 2008). Author weblink.
  • Magliozzi R; Howell OW; Durrenberger PF; Roncacroli F; Nicholas R; Aloisi F; Reynolds R. Substantial neuronal loss and microglia activation in MS grey matter are associated with increased meningeal inflammation. BrainNet Europe 2nd International Conference on Human Brain Tissue Research, 10 Dec 2008 - 12 Dec 2008. 115:1731-1731. SPRINGER WIEN (1 Dec 2008). Author weblink.
  • Gveric D; Nicholas R; Roncaroli F; Gentleman S; Reynolds R. The UK multiple sclerosis tissue bank: target validation made easy. BrainNet Europe 2nd International Conference on Human Brain Tissue Research, 10 Dec 2008 - 12 Dec 2008. 115:1731-1731. SPRINGER WIEN (1 Dec 2008). Author weblink.
  • Reynolds R; Magliozzi R; Nicholas R; Roncaroli F; Durrenberger P; Serafini B; Aloisi F; Howell O. Cortical pathology in multiple sclerosis is associated with substantial neurodegeneration and progressive neurological disability. BrainNet Europe 2nd International Conference on Human Brain Tissue Research, 10 Dec 2008 - 12 Dec 2008. 115:1718-1719. SPRINGER WIEN (1 Dec 2008). Author weblink.
  • Balaratnam M; Adib-Sami P; D'Arcy C; Nicholas RS; Malik O. Community based disciplinary multiple sclerosis clinics reduce hospital bed occupancy and enhance patient satisfaction. Annual Meeting of the Association-of-British-Neurologists, 14 Nov 2007 - 16 Nov 2007. 79:339-340. B M J PUBLISHING GROUP (1 Mar 2008). Author weblink.
  • Dukes SON; Patel R; Papadopoulos D; Vora A; Nicholas RS; Reynolds R. Archaeocortical lesions in multiple sclerosis: A quantitive histopathological study. Annual Meeting of the Association-of-British-Neurologists, 14 Nov 2007 - 16 Nov 2007. 79:339-339. B M J PUBLISHING GROUP (1 Mar 2008). Author weblink.
  • Mills RJ; Vora AJ; Reynolds R; Nicholas RS. Predicting disability in multiple sclerosis using the MSIS-29. 23rd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis/12th Annual Conference of Rehabilitation in MS, 11 Oct 2007 - 14 Oct 2007. 13:S117-S117. SAGE PUBLICATIONS LTD (1 Oct 2007). Author weblink.
  • Magliozzi R; Howell O; Nicholas R; Fernando F; Serafini B; Aloisi F; Reynolds R. Extensive cortical cell loss is associated with the presence of meningeal B-cell follicles in secondary progressive multiple sclerosis. 23rd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis/12th Annual Conference of Rehabilitation in MS, 11 Oct 2007 - 14 Oct 2007. 13:S16-S17. SAGE PUBLICATIONS LTD (1 Oct 2007). Author weblink.
  • Mills RJ; Nicholas RS; Malik O; Young CA. Rasch analysis of the fatigue severity scale in multiple sclerosis. 11th Congress of the European-Federation-of-Neurological-Societies. 14:285-285. (Aug 2007).
  • Nicholas RS; Magliozzi R; Howell O; Vora A; Serafini B; Puopolo M; Reynolds R; Aloisi F. Meningeal B cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. ABN Spring Scientific Meeting 2007. 78:1032-1032. (Sep 2007).
  • Mills RJ; Nicholas R; Malik O; Young CA. Rasch analysis of the Modified Fatigue Impact Scale in multiple sclerosis. ABN Spring Scientific Meeting 2007, 11 Apr 2007 - 13 Apr 2007. 78:1034-1034. B M J PUBLISHING GROUP (1 Sep 2007). Author weblink.
  • Vora A; Patel N; Ghebrenegus I; Graeber M; Gentleman SM; Roncaroli F; Malik O; Nicholas R; et alReynolds R. The UK Multiple Sclerosis Tissue Bank - a resource for research. 106th Annual Meeting of the British-Neuropathological-Society. 31:240-241. (Apr 2005).
  • Nicholas RS; Roncaroli F; Vora AJ; Gentleman SM; Graeber MG; Malik O; Reynolds RC. The pathological basis of disability in multiple sclerosis subjects with frequent early relapses. 21st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis/10th Annual Meeting of Rehabilitation in MS. 11:S41-S42. (Sep 2005).
  • Nicholas RS; Roncaroli F; Vora AJ; Gentleman SM; Graeber MB; Malik O; Reynolds R. Seizures in multiple sclerosis (MS): Is grey matter damage the culprit?. Clinical Neurosciences 2005 Meeting. 77:140-140. (Jan 2006).
  • Vora AJ; Malik O; Nicholas R; Graeber M; Roncaroli F; Gentleman S; Reynolds R. The UK Multiple Sclerosis Tissue Bank - a resource for research. 18th World Congress of Neurology. 238:S254-S254. (15 Nov 2005).
  • Magliozzi R; Vora A; Serafini B; Nicholas R; Howell O; Puopolo M; Reynolds R; Aloisi F. Pathological relevance of meningeal B-cell follicles in secondary progressive multiple sclerosis. 22nd Congress of the European-Committee-for-the-Treatment-and-Resarch-in-Multiple-Sclerosis. 12:S223-S224. (Sep 2006).
  • Vora AJ; Taylor K; Ghebrenegus I; Gentleman SM; Roncaroli F; Malik O; Reynolds RC; Nicholas RS. Brain weight in multiple sclerosis-independent of clinical parameters. 21st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis/10th Annual Meeting of Rehabilitation in MS, 28 Sep 2005 - 1 Oct 2005. 11:S42-S42. HODDER ARNOLD, HODDER HEADLINE PLC (1 Sep 2005). Author weblink.
  • Wakerley B; Jacob A; Ramtahal J; Rashid S; Polito B; Chataway J; Young C; Boggild M; et alMalik O; Nicholas R. Population characteristics may contribute to the success or failure of disease modifying therapy in multiple sclerosis. Spring Meeting of the Association-of-British-Neurologists, 19 Apr 2006 - 21 Apr 2006. 77:1389-1389. B M J PUBLISHING GROUP (1 Dec 2006). Author weblink.
Share this on Delicious
Tweet this
Digg this
Stumble this
Share this on Facebook